|
US5700913A
(en)
|
1982-12-15 |
1997-12-23 |
Ajinomoto Co., Inc. |
Unglycosylated human interleukin-2 polypeptides
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
IL80678A
(en)
|
1985-11-19 |
1999-05-09 |
Schering Biotech Corp |
Human interleukin-4
|
|
US6028186A
(en)
|
1991-06-10 |
2000-02-22 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of cytokines
|
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
|
US7008624B1
(en)
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
ZA967182B
(en)
|
1995-08-24 |
1998-05-25 |
Magainin Pharma |
Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
|
|
IL130238A0
(en)
|
1999-06-01 |
2000-06-01 |
Peptor Ltd |
Conformationally constrained backbone cyclized interleukin-6 antagonists
|
|
AU2937597A
(en)
|
1996-05-10 |
1997-12-05 |
Biogen, Inc. |
Common gamma chain blocking agents
|
|
US6127387A
(en)
|
1996-12-10 |
2000-10-03 |
Thomas Jefferson University |
Use of CD4-binding small molecules to inhibit immune responses
|
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
|
US6861227B2
(en)
|
1998-03-19 |
2005-03-01 |
Human Genome Sciences, Inc. |
Antibodies to cytokine receptor common gamma chain like
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EP0972780A1
(en)
|
1998-05-18 |
2000-01-19 |
Applied Research Systems ARS Holding N.V. |
Il-6 antagonist peptides
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
|
EP1284747A2
(en)
|
2000-05-12 |
2003-02-26 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for achieving immune suppression
|
|
EP1349873B1
(en)
|
2000-09-14 |
2009-04-01 |
Beth Israel Deaconess Medical Center, Inc. |
Modulation of il-2- and il-15-mediated t cell responses
|
|
CA2425506A1
(en)
|
2000-10-18 |
2002-08-01 |
Immunex Corporation |
Methods for treating rheumatoid arthritis using il-17 antagonists
|
|
WO2003004098A1
(en)
|
2001-07-06 |
2003-01-16 |
Sucampo Ag |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
|
CA2465268A1
(en)
|
2001-10-24 |
2003-05-01 |
National Jewish Medical And Research Center |
Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
|
|
ES2334338T3
(es)
|
2001-11-05 |
2010-03-09 |
Zymogenetics, Inc. |
Antagonistas de il-21.
|
|
EP2840089A1
(en)
|
2002-01-18 |
2015-02-25 |
ZymoGenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
WO2003087320A2
(en)
|
2002-04-09 |
2003-10-23 |
Beth Israel Deaconess Medical Center, Inc. |
Antagonists of il-21 and modulation of il-21-mediated t cell responses
|
|
AU2003243189B2
(en)
|
2002-05-01 |
2008-01-24 |
Regeneron Pharmaceuticals, Inc. |
Methods of using cytokine antagonists to treat HIV infection and AIDS
|
|
DK1531850T3
(da)
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
|
AU2002368055B2
(en)
|
2002-06-28 |
2008-09-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
|
|
AU2003251633A1
(en)
|
2002-07-01 |
2004-01-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Il-21 as a regulator of immunoglobin production
|
|
US7314623B2
(en)
|
2002-07-15 |
2008-01-01 |
Wyeth |
Methods and compositions for modulating T helper (Th) cell development and function
|
|
CN1703423A
(zh)
|
2002-10-14 |
2005-11-30 |
豪夫迈－罗氏公司 |
Il－15拮抗剂
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
CA2518854A1
(en)
|
2003-03-21 |
2004-10-07 |
Wyeth |
Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
|
|
DE602004028007D1
(de)
|
2003-05-14 |
2010-08-19 |
Bayer Pharmaceuticals Corp |
Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren
|
|
WO2004112703A2
(en)
|
2003-06-19 |
2004-12-29 |
Centocor, Inc. |
Interleukin-21 analogs
|
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7785580B2
(en)
|
2003-08-29 |
2010-08-31 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
|
EP1670501A2
(en)
|
2003-09-25 |
2006-06-21 |
ZymoGenetics, Inc. |
Methods of treating autoimmune diseases using il-21
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
EP1708737A2
(en)
|
2004-01-15 |
2006-10-11 |
Novo Nordisk A/S |
Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
|
|
EP1751175B1
(en)
|
2004-05-05 |
2012-07-25 |
VALORISATION-RECHERCHE, Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
|
EP1753458A4
(en)
|
2004-05-19 |
2009-07-22 |
Wyeth Corp |
MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
|
|
RU2007102287A
(ru)
|
2004-08-05 |
2008-09-10 |
Вайет (Us) |
Антагонисты активности рецептора интерлейкина-21
|
|
CU23472A1
(es)
|
2004-09-17 |
2009-12-17 |
Ct Ingenieria Genetica Biotech |
Péptido antagonista de la interleucina-15
|
|
WO2006105538A2
(en)
|
2005-03-31 |
2006-10-05 |
Centocor, Inc. |
Methods and compositions for treating il-21 related pathologies
|
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
CA2604222A1
(en)
|
2005-04-18 |
2006-10-26 |
Novo Nordisk A/S |
Il-21 variants
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US8512946B2
(en)
|
2005-08-10 |
2013-08-20 |
Northwestern University |
Composite particles
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
WO2007111714A2
(en)
|
2005-11-28 |
2007-10-04 |
Zymogenetics, Inc. |
Il-21 antagonists
|
|
WO2008031064A1
(en)
|
2006-09-07 |
2008-03-13 |
University Of South Florida |
Hyd1 peptides as anti-cancer agents
|
|
JP2010507382A
(ja)
|
2006-10-26 |
2010-03-11 |
ノヴォ ノルディスク アクティーゼルスカブ |
Ｉｌ−２１変異体
|
|
US8211420B2
(en)
|
2006-12-21 |
2012-07-03 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the IL-21 receptor
|
|
US7910123B2
(en)
|
2007-09-05 |
2011-03-22 |
Warsaw Orthopedic |
Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
|
|
WO2009100035A2
(en)
|
2008-02-01 |
2009-08-13 |
Wyeth |
Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
|
|
EP2254998B1
(en)
|
2008-02-28 |
2015-12-23 |
Argos Therapeutics, Inc. |
Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
|
|
WO2009132821A1
(en)
|
2008-04-28 |
2009-11-05 |
Giuliani International Limited |
Interleukin (il-21) binding proteins and methods of making and using same
|
|
US20110091515A1
(en)
|
2008-06-12 |
2011-04-21 |
Ramot At Tel-Aviv University Ltd. |
Drug-eluting medical devices
|
|
EP2356139A4
(en)
*
|
2008-07-23 |
2013-01-09 |
Harvard College |
LIGURE COMBINED POLYPEPTIDES
|
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
NZ592943A
(en)
|
2008-11-17 |
2012-09-28 |
Uinv Kobenhavns |
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
|
|
EP2384337A1
(en)
|
2009-01-05 |
2011-11-09 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
|
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Ｉｌ－１７結合蛋白
|
|
EP2406282A1
(en)
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
AU2010273220B2
(en)
|
2009-07-13 |
2015-10-15 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
CN102753574B
(zh)
|
2009-12-11 |
2015-05-20 |
西马生物医学计划公司 |
用于免疫治疗和抗肿瘤治疗的缀合物和组合物
|
|
WO2011105520A1
(ja)
|
2010-02-26 |
2011-09-01 |
国立大学法人 長崎大学 |
抗原または薬物送達複合体
|
|
US9782454B2
(en)
|
2010-04-22 |
2017-10-10 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
US8822642B2
(en)
|
2010-06-09 |
2014-09-02 |
Zymogenetics, Inc. |
Dimeric fusion proteins and related compositions and methods
|
|
US9084761B2
(en)
|
2010-07-09 |
2015-07-21 |
The Regents Of The University Of California |
Use of interleukin-15 to treat cardiovascular diseases
|
|
WO2012012531A2
(en)
|
2010-07-20 |
2012-01-26 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods featuring il-6 and il-21 antagonists
|
|
EP2665486B1
(en)
|
2011-01-18 |
2019-12-25 |
Bioniz, LLC |
Compositions for modulating gamma-c-cytokine activity
|
|
US20240043475A1
(en)
|
2011-01-18 |
2024-02-08 |
Bioniz, Llc |
Peptide conjugates
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
US9959384B2
(en)
|
2013-12-10 |
2018-05-01 |
Bioniz, Llc |
Methods of developing selective peptide antagonists
|
|
WO2017046200A1
(en)
|
2015-09-16 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
|
|
WO2017062685A1
(en)
|
2015-10-09 |
2017-04-13 |
Bioniz, Llc |
Modulating gamma - c -cytokine activity
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
US12600757B2
(en)
|
2017-04-07 |
2026-04-14 |
Bioniz Therapeutics, Inc. |
Peptides inhibiting gamma-c-cytokine activity and methods of use
|
|
CA3137971A1
(en)
|
2019-05-03 |
2020-11-12 |
Bioniz, Llc |
Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
|
|
EP4172175A4
(en)
|
2020-06-24 |
2024-07-24 |
Bioniz Therapeutics, Inc. |
Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders
|